Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,724 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Outcomes of second allogeneic haematopoietic stem cell transplantation in patients with relapse of myelodysplastic syndrome.
Shimomura Y, Hara M, Tachibana T, Ohashi K, Sakura T, Fukuda T, Nakazawa H, Iwato K, Kanda Y, Ikeda T, Eto T, Kanda J, Ichinohe T, Atsuta Y, Ishikawa T, Ishiyama K. Shimomura Y, et al. Among authors: hara m. Br J Haematol. 2019 Jul;186(1):86-90. doi: 10.1111/bjh.15898. Epub 2019 Apr 2. Br J Haematol. 2019. PMID: 30941758 Free article.
Measurable residual disease evaluated by flow cytometry using leukemia associated immune phenotypes following allogeneic stem cell transplantation is associated with high relapse rates in patients with acute myeloid leukemia.
Shimomura Y, Hara M, Maruoka H, Yabushita T, Ishikawa T. Shimomura Y, et al. Among authors: hara m. Leuk Lymphoma. 2020 Mar;61(3):745-748. doi: 10.1080/10428194.2019.1686500. Epub 2019 Nov 11. Leuk Lymphoma. 2020. PMID: 31710240 No abstract available.
Allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome in adolescent and young adult patients.
Shimomura Y, Hara M, Konuma T, Itonaga H, Doki N, Ozawa Y, Eto T, Uchida N, Aoki J, Kato J, Onishi Y, Takahashi S, Fukushima K, Nakamae H, Kawakita T, Tanaka J, Fukuda T, Atsuta Y, Ishikawa T, Ishiyama K. Shimomura Y, et al. Among authors: hara m. Bone Marrow Transplant. 2021 Oct;56(10):2510-2517. doi: 10.1038/s41409-021-01324-8. Epub 2021 May 15. Bone Marrow Transplant. 2021. PMID: 33993196
Adding melphalan to fludarabine and a myeloablative dose of busulfan improved survival after allogeneic hematopoietic stem cell transplantation in a propensity score-matched cohort of hematological malignancies.
Shimomura Y, Hara M, Yamamoto H, Uchida N, Kawakita T, Ashida T, Takada S, Ikeda T, Morishige S, Maruyama Y, Wake A, Ichinohe T, Fukuda T, Takanashi M, Atsuta Y, Ishikawa T. Shimomura Y, et al. Among authors: hara m. Bone Marrow Transplant. 2021 Jul;56(7):1691-1699. doi: 10.1038/s41409-021-01217-w. Epub 2021 Mar 3. Bone Marrow Transplant. 2021. PMID: 33658646
Comparison of fludarabine, a myeloablative dose of busulfan, and melphalan vs conventional myeloablative conditioning regimen in patients with relapse and refractory acute myeloid leukemia in non-remission status.
Shimomura Y, Hara M, Hirabayashi S, Kondo T, Mizuno S, Uchida N, Mukae J, Kawakita T, Fukuda T, Kanda Y, Ota S, Ozawa Y, Eto T, Maruyama Y, Tanaka M, Nakano N, Kimura T, Ichinohe T, Atsuta Y, Yanada M. Shimomura Y, et al. Among authors: hara m. Bone Marrow Transplant. 2021 Sep;56(9):2302-2304. doi: 10.1038/s41409-021-01380-0. Epub 2021 Jun 21. Bone Marrow Transplant. 2021. PMID: 34155357 No abstract available.
Comparison of Autologous and Unrelated Transplants for Cytogenetically Normal Acute Myelogenous Leukemia.
Mizutani M, Takami A, Hara M, Mizuno S, Yanada M, Chou T, Uchiyama H, Ohashi K, Miyamoto T, Ozawa Y, Imataki O, Kobayashi N, Uchida N, Kanamori H, Kamimura T, Eto T, Onizuka M, Tanaka J, Atsuta Y, Yano S. Mizutani M, et al. Among authors: hara m. Biol Blood Marrow Transplant. 2017 Sep;23(9):1447-1454. doi: 10.1016/j.bbmt.2017.05.008. Epub 2017 May 19. Biol Blood Marrow Transplant. 2017. PMID: 28533061 Free article.
3,724 results